Science & Research
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
AI System Detects Pancreatic Cancer Signs Three Years Before Diagnosis
Mayo Clinic researchers have developed an AI system that identifies early warning signs of pancreatic cancer up to three years before formal diagnosis, potentially enabling earlier intervention and improved outcomes.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Wellness Index Report Reveals Top Providers in Superhuman Protocol Challenge, Marking Shift to Cellular-Level Health
The April 2026 Wellness Index Report identifies Physical Evidence Chiropractic, Boro Holistic Health, and April Berkowitz as leading providers in the Superhuman Protocol Challenge, signaling a move from seasonal weight-loss trends to system-level health optimization.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
Canamera Energy Metals Engages ExploreTech to Optimize Drilling at Schryburt Lake REE-Niobium Project
Canamera Energy Metals Corp. has hired ExploreTech for an independent geophysical review and drill optimization at its Schryburt Lake REE-Niobium Project in Ontario, aiming to refine targets and expedite a 1,500-meter drilling program pending permit approval.
VolitionRx Reports High Accuracy in Feline Cancer Blood Test, Unlocking $5M Milestone
VolitionRx's Nu.Q Vet prototype assay shows 97% specificity in detecting feline lymphoma, advancing a liquid biopsy for cats and unlocking a $5 million contractual milestone upon peer-reviewed publication.
New Study Reveals How Cancer Reprograms Immune Cells, Offering Hope for Immunotherapy Breakthrough
A study uncovering how cancer cells reprogram immune cells to support tumor growth could improve immunotherapy response rates, which currently fail in 80% of patients.
MilliporeSigma Expands Temecula Biotech Hub, Advancing Organoid Research and Personalized Medicine
MilliporeSigma's investments in Temecula, including a new organoid lab and acquisition of HUB Organoids, position the site at the forefront of disease modeling and personalized medicine, while reinforcing its community commitment.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
Aclarion Expands Nociscan Use at Weill Cornell Medicine in New Trial on Disc Degeneration
Aclarion's second commercial agreement with Weill Cornell Medicine will deploy its Nociscan platform in a randomized controlled trial led by Dr. Roger Härtl, aiming to improve understanding and treatment of degenerative disc disease.
Vitamin D Supplement Found to Boost Chemotherapy Efficacy in Breast Cancer Patients
A Brazilian clinical trial reveals that daily vitamin D supplementation improves outcomes for women undergoing standard chemotherapy for breast cancer, highlighting a low-cost intervention with global implications.
New Book Aims to Close Awareness Gap on Women's Heart Disease Symptoms
Cardiologist Arash Bereliani releases 'What About Her Heart' to educate the public on how heart disease presents differently in women, addressing a critical gap in recognition and timely diagnosis.
NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
New Study Links Breast Tissue Aging to Increased Breast Cancer Risk in Older Women
Research mapping breast tissue changes with age explains higher breast cancer rates in older women and may guide new treatments.
Powermax Minerals Refines Exploration Strategy at Atikokan, Identifies High-Priority Rare Earth Zones
Powermax Minerals has integrated geochemical and geophysical data to pinpoint priority target zones for rare earth elements at its Atikokan property in Ontario, advancing from early-stage sampling to targeted exploration.
Cardio Diagnostics Leverages AI and Biomarkers to Combat Cardiovascular Disease
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is advancing early detection of heart disease using a platform that combines artificial intelligence with multi-omic biomarker analysis, addressing the urgent need for innovation in cardiovascular care.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Stopping the ‘Silent Killer’: How to Check, Prevent and Manage High Blood Pressure
American Heart Association highlights that nearly half of U.S. adults have high blood pressure, many undiagnosed, and emphasizes lifestyle changes and monitoring to prevent heart disease and stroke.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
Three Breakthroughs Indicate Quantum Computing May Arrive Sooner Than Expected
Recent advancements in hardware stability, real-world problem-solving, and error correction resource requirements suggest quantum computing could become practical earlier than projected.
Lexaria Bioscience Extends Material Transfer Agreement with PharmaCO Through 2026
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company to evaluate its DehydraTECH technology for GLP-1 drugs, allowing for continued collaboration and review of upcoming R&D results.